[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse BCOR

Summary
SymbolBCOR
NameBCL6 corepressor
Aliases FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal LocationXp11.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF12796 Ankyrin repeats (3 copies)
PF15808 BCL-6 co-repressor
PF16553 BCORL-PCGF1-binding domain
Function

Transcriptional corepressor. May specifically inhibit gene expression when recruited to promoter regions by sequence-specific DNA-binding proteins such as BCL6 and MLLT3. This repression may be mediated at least in part by histone deacetylase activities which can associate with this corepressor. Involved in the repression of TFAP2A; impairs binding of BCL6 and KDM2B to TFAP2A promoter regions. Via repression of TFAP2A acts as a negative regulator of osteo-dentiogenic capacity in adult stem cells; the function implies inhibition of methylation on histone H3 'Lys-4' (H3K4me3) and 'Lys-36' (H3K36me2).

> Gene Ontology
 
Biological Process GO:0000414 regulation of histone H3-K36 methylation
GO:0000415 negative regulation of histone H3-K36 methylation
GO:0001503 ossification
GO:0006479 protein methylation
GO:0006513 protein monoubiquitination
GO:0007389 pattern specification process
GO:0007507 heart development
GO:0008213 protein alkylation
GO:0009798 axis specification
GO:0010390 histone monoubiquitination
GO:0010452 histone H3-K36 methylation
GO:0016570 histone modification
GO:0016571 histone methylation
GO:0016574 histone ubiquitination
GO:0018022 peptidyl-lysine methylation
GO:0018205 peptidyl-lysine modification
GO:0030278 regulation of ossification
GO:0030279 negative regulation of ossification
GO:0030282 bone mineralization
GO:0030500 regulation of bone mineralization
GO:0030502 negative regulation of bone mineralization
GO:0031056 regulation of histone modification
GO:0031057 negative regulation of histone modification
GO:0031060 regulation of histone methylation
GO:0031061 negative regulation of histone methylation
GO:0031214 biomineral tissue development
GO:0032259 methylation
GO:0033522 histone H2A ubiquitination
GO:0034505 tooth mineralization
GO:0034968 histone lysine methylation
GO:0035518 histone H2A monoubiquitination
GO:0042476 odontogenesis
GO:0042481 regulation of odontogenesis
GO:0042483 negative regulation of odontogenesis
GO:0043414 macromolecule methylation
GO:0051568 histone H3-K4 methylation
GO:0051569 regulation of histone H3-K4 methylation
GO:0051572 negative regulation of histone H3-K4 methylation
GO:0060021 palate development
GO:0065001 specification of axis polarity
GO:0070167 regulation of biomineral tissue development
GO:0070168 negative regulation of biomineral tissue development
GO:0070170 regulation of tooth mineralization
GO:0070171 negative regulation of tooth mineralization
GO:1902275 regulation of chromatin organization
GO:1905268 negative regulation of chromatin organization
GO:2000027 regulation of organ morphogenesis
Molecular Function GO:0003714 transcription corepressor activity
GO:0004842 ubiquitin-protein transferase activity
GO:0008134 transcription factor binding
GO:0019787 ubiquitin-like protein transferase activity
GO:0031072 heat shock protein binding
GO:0042826 histone deacetylase binding
Cellular Component GO:0031519 PcG protein complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolBCOR
NameBCL6 corepressor
Aliases FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal LocationXp11.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BCOR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between BCOR and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27505670Diffuse Large B Cell LymphomaInhibit immunityHerein we show that the actions of EZH2 in driving GC formation and lymphoma precursor lesions require site-specific binding by the BCL6 transcriptional repressor and the presence of a non-canonical PRC1-BCOR-CBX8 complex. The chromodomain protein CBX8 is induced in GC B cells, binds to H3K27me3 at bivalent promoters, and is required for stable association of the complex and the resulting histone modifications. Moreover, oncogenic BCL6 and EZH2 cooperate to accelerate diffuse large B cell lymphoma (DLBCL) development and combinatorial targeting of these repressors results in enhanced anti-lymphoma activity in DLBCLs.
Summary
SymbolBCOR
NameBCL6 corepressor
Aliases FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal LocationXp11.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BCOR in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolBCOR
NameBCL6 corepressor
Aliases FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal LocationXp11.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BCOR in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1120.598
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.380.784
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0860.935
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4980.149
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.410.85
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6090.824
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2840.388
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2140.888
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3760.823
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.810.513
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1750.517
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0460.498
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of BCOR in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.37.4-2.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolBCOR
NameBCL6 corepressor
Aliases FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal LocationXp11.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BCOR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBCOR
NameBCL6 corepressor
Aliases FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal LocationXp11.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BCOR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BCOR.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBCOR
NameBCL6 corepressor
Aliases FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal LocationXp11.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BCOR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBCOR
NameBCL6 corepressor
Aliases FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal LocationXp11.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BCOR expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBCOR
NameBCL6 corepressor
Aliases FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal LocationXp11.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BCOR and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBCOR
NameBCL6 corepressor
Aliases FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal LocationXp11.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BCOR collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.